ERBB2 and breast carcinoma: Immunohistochemical studies in tumor biopsies have linked increased HIF-1α protein levels with an increased risk of metastasis and mortality in lymph node-positive, lymph node-negative, Her2+, ER+, and unselected breast cancer patients [4].